Skip to main content
Clinical Trials/NCT00221676
NCT00221676
Completed
Phase 4

Effectiveness of Influenza Vaccination (Alfarix)in Preventing Clinical Influenza Cases Among General Practitioners: Non-Randomized Clinical Trial.

University Hospital, Antwerp0 sites300 target enrollmentJuly 2002
ConditionsInfluenza

Overview

Phase
Phase 4
Intervention
Not specified
Conditions
Influenza
Sponsor
University Hospital, Antwerp
Enrollment
300
Primary Endpoint
number of respiratory tract infections
Status
Completed
Last Updated
19 years ago

Overview

Brief Summary

Besides the personal protection, influenza vaccination especially needs to prevent transmission of influenza between GPs and their patients. The question remains if the vaccine is adding substantial benefit to the natural acquired immunity of GPs. Doubts are raised if an inactivated vaccine, which elicit especially humoral immune response, can give enough protection against virus replication and subclinical influenza infections. Until now no effectiveness studies of influenza vaccination were performed among GPs. This study will assess the effectiveness of an inactivated influenza vaccine in GPs against clinical respiratory tract infections and more particular against influenza cases with influenza positive nose and throat swabs (diagnosed by RT-PCR).

Detailed Description

Two important aspects emerge when considering influenza vaccination of general practitioners as advocated by many guidelines. Besides the personal protection the vaccine especially needs to prevent transmission of influenza between GPs and their patients. In long-term elderly hospitals a possible benefit of influenza vaccination of the healthcare workers was noticed in reducing mortality among the elderly. But this specific situation is not fully transmissible to the general practice. GPs, having yearly close contact with several influenza cases, built up a high basic immunity and probably only suffer from minor symptoms. The question remains if the vaccine is adding substantial benefit to this natural acquired immunity. In addition doubts are raised in the literature if an inactivated vaccine, which elicit especially humoral immune response, can give enough protection against virus replication and subclinical influenza infections. Until now no effectiveness studies of influenza vaccination were performed among GPs. High time to look more closer to these issues. Comparisons: the effectiveness of an inactivated influenza vaccine compared with no vaccine in GPs against clinical respiratory tract infections and more particular against influenza cases with influenza positive nose and throat swabs (diagnosed by RT-PCR), besides serological defined influenza cases and taking important independent variables into account

Registry
clinicaltrials.gov
Start Date
July 2002
End Date
June 2004
Last Updated
19 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • general practitioner with an active practice in Flanders, Belgium -

Exclusion Criteria

  • other specialists in medicine

Outcomes

Primary Outcomes

number of respiratory tract infections

number of influenza cases defined as a RTI with positive nose and throat swabs

number of influenza cases defined as a RTI with 4-fold IgG titre rise

Similar Trials